**SUPPLEMENTAL DIGITAL CONTENT**

**List of Supplemental Digital Content:**

Supplemental Digital Content 1.docx

*Search terms used to identify relevant articles*

Supplemental Digital Content 2.docx

*Table S2. Incidence of low birth weight and prematurity in pregnancy after transplantation*

Supplemental Digital Content 3.docx

*Table S3****.*** *Case reports: pregnancy outcomes in women on MPA treatment*

**Supplemental Digital Content 1.** Search terms used to identify relevant articles

Embase:

('tacrolimus'/de OR 'mycophenolic acid'/de OR 'mycophenolate mofetil'/de OR (tacrolim\* OR prograft\* OR mycophenol\* OR FK-506 OR FK506 OR FR-900506 OR FR900506 OR cellcept OR myfortic OR RS-61443 OR RS61443):ab,ti) AND ('pregnant woman'/de OR 'lactation'/de OR 'pregnancy outcome'/de OR 'embryo'/de OR 'fetus'/de OR 'pregnancy'/exp OR 'fertility'/exp OR 'teratogenicity'/de OR 'pregnancy disorder'/exp OR 'birth'/exp OR (neonat\* OR newborn\* OR new-born\* OR childbirth\* OR stillbirth\* OR birth\* OR parturition\* OR transplacental\* OR placenta\* OR abortion\* OR teratogenicit\* OR teratogeneit\* OR lactat\* OR lactic\* OR eclamp\* OR preeclamp\* OR pre-eclamp\* OR embryo OR embryopath\* OR fecundit\* OR sperm-ovum\* OR fertilit\* OR pregnant\* OR pregnanc\* OR feto OR fetomaternal\* OR fetus\* OR foetus\* OR fetal OR fetalmaternal\* OR foetal\* OR childbear\* OR gestat\* OR gravid\* OR labor OR labour OR ((child\*) NEAR/3 (bear\*)) OR ((breast\* OR mamma\* OR milk\*) NEAR/3 (secret\* OR excret\* OR releas\*))):ab,ti) AND ('transplantation'/exp OR (transplant\* OR allograft\* OR allotransplant\* OR autograft\* OR autotransplant\* OR graft\* OR isograft\* OR isotransplant\* OR retransplant\* OR xenograft\* OR xenotransplant\* OR inplant OR implant OR homograft\* OR homotransplant\*):ab,ti) NOT ([animals]/lim NOT [humans]/lim) AND [english]/lim NOT ([Conference Abstract]/lim)

Medline:

(Tacrolimus/ OR Mycophenolic Acid/ OR (tacrolim\* OR prograft\* OR mycophenol\* OR FK-506 OR FK506 OR FR-900506 OR FR900506 OR cellcept OR myfortic OR RS-61443 OR RS61443).ab,ti.) AND (Pregnant Women/ OR Lactation/ OR exp Pregnancy Outcome/ OR exp Fetus/ OR exp Pregnancy/ OR exp Fertility/ OR Teratogenesis/ OR exp Pregnancy Complications/ OR exp Parturition/ OR (neonat\* OR newborn\* OR new-born\* OR childbirth\* OR stillbirth\* OR birth\* OR parturition\* OR transplacental\* OR placenta\* OR abortion\* OR teratogenicit\* OR teratogeneit\* OR lactat\* OR lactic\* OR eclamp\* OR preeclamp\* OR pre-eclamp\* OR embryo OR embryopath\* OR fecundit\* OR sperm-ovum\* OR fertilit\* OR pregnant\* OR pregnanc\* OR feto OR fetomaternal\* OR fetus\* OR foetus\* OR fetal OR fetalmaternal\* OR foetal\* OR childbear\* OR gestat\* OR gravid\* OR labor OR labour OR ((child\*) ADJ3 (bear\*)) OR ((breast\* OR mamma\* OR milk\*) ADJ3 (secret\* OR excret\* OR releas\*))).ab,ti.) AND (exp Transplantation/ OR (transplant\* OR allograft\* OR allotransplant\* OR autograft\* OR autotransplant\* OR graft\* OR isograft\* OR isotransplant\* OR retransplant\* OR xenograft\* OR xenotransplant\* OR inplant OR implant OR homograft\* OR homotransplant\*).ab,ti.) NOT (exp animals/ NOT humans/) AND english.la. NOT (news OR congres\* OR abstract\* OR book\* OR chapter\* OR dissertation abstract\*).pt.

Cochrane (RCTs):

((tacrolim\* OR prograft\* OR mycophenol\* OR (FK NEXT/1 506) OR FK506 OR (FR NEXT/1 900506) OR FR900506 OR cellcept OR myfortic OR (RS NEXT/1 61443) OR RS61443):ab,ti) AND ((neonat\* OR newborn\* OR (new NEXT/1 born\*) OR childbirth\* OR stillbirth\* OR birth\* OR parturition\* OR transplacental\* OR placenta\* OR abortion\* OR teratogenicit\* OR teratogeneit\* OR lactat\* OR lactic\* OR eclamp\* OR preeclamp\* OR (pre NEXT/1 eclamp\*) OR embryo OR embryopath\* OR fecundit\* OR (sperm NEXT/1 ovum\*) OR fertilit\* OR pregnant\* OR pregnanc\* OR feto OR fetomaternal\* OR fetus\* OR foetus\* OR fetal OR fetalmaternal\* OR foetal\* OR childbear\* OR gestat\* OR gravid\* OR labor OR labour OR ((child\*) NEAR/3 (bear\*)) OR ((breast\* OR mamma\* OR milk\*) NEAR/3 (secret\* OR excret\* OR releas\*))):ab,ti) AND ((transplant\* OR allograft\* OR allotransplant\* OR autograft\* OR autotransplant\* OR graft\* OR isograft\* OR isotransplant\* OR retransplant\* OR xenograft\* OR xenotransplant\* OR inplant OR implant OR homograft\* OR homotransplant\*):ab,ti)

Web of Science:

TS=(((tacrolim\* OR prograft\* OR mycophenol\* OR FK-506 OR FK506 OR FR-900506 OR FR900506 OR cellcept OR myfortic OR RS-61443 OR RS61443)) AND ((neonat\* OR newborn\* OR new-born\* OR childbirth\* OR stillbirth\* OR birth\* OR parturition\* OR transplacental\* OR placenta\* OR abortion\* OR teratogenicit\* OR teratogeneit\* OR lactat\* OR lactic\* OR eclamp\* OR preeclamp\* OR pre-eclamp\* OR embryo OR embryopath\* OR fecundit\* OR sperm-ovum\* OR fertilit\* OR pregnant\* OR pregnanc\* OR feto OR fetomaternal\* OR fetus\* OR foetus\* OR fetal OR fetalmaternal\* OR foetal\* OR childbear\* OR gestat\* OR gravid\* OR labor OR labour OR ((child\*) NEAR/2 (bear\*)) OR ((breast\* OR mamma\* OR milk\*) NEAR/2 (secret\* OR excret\* OR releas\*)))) AND ((transplant\* OR allograft\* OR allotransplant\* OR autograft\* OR autotransplant\* OR graft\* OR isograft\* OR isotransplant\* OR retransplant\* OR xenograft\* OR xenotransplant\* OR inplant OR implant OR homograft\* OR homotransplant\*)) NOT ((animal\* OR rat OR rats OR mouse OR mice OR murine OR dog OR dogs OR canine OR cat OR cats OR feline OR rabbit OR cow OR cows OR bovine OR rodent\* OR sheep OR ovine OR pig OR swine OR porcine OR veterinar\* OR chick\* OR zebrafish\* OR baboon\* OR nonhuman\* OR primate\* OR cattle\* OR goose OR geese OR duck OR macaque\* OR avian\* OR bird\* OR fish\*) NOT (human\* OR patient\* OR women OR woman OR men OR man))) AND DT=(Article OR Review) AND LA=(English)('tacrolimus'/de OR 'mycophenolic acid'/de OR 'mycophenolate mofetil'/de

Google Scholar:

tacrolimus|prograft|"mycophenolic acid"|myfortic stillbirth|birth|abortion|teratogenicity|teratogeneity|lactation|fertility|pregnant|pregnancy|gestation|gravidity transplant|allograft|allotransplant|autograft|autotransplant|graft|xenograft|xenotransplant|homograft|homotransplant

**Supplemental Digital Content 2.**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Table S2.** Incidence of low birth weight and prematurity in pregnancy after transplantation. | | | | | | | | | | |
| **Article, year** | **Pregnancy (n)** | **Organ transplantation** | **Drug** | **Livebirths** | **Birth weight (g)** | **LBW** | **Gestation (weeks)** | **Prematurity** | **Small for gestational age** |
| Kainz *et al.*, 2000 6 | 100 | Liver, kidney, heart, pancreas, lung | Tac | 68% | 2573 | N.A. | 35 | 59% | 10% |
| Armenti *et al.*, 2000 83 | 23 | Liver | Tac |  | 3021 | 17% | 37.4 | 33% |  |
| Carr *et al.,* 2000 84 | 6 | Liver | 50% Tac |  | 1727 | 67% | 33 | 50% |  |
| Nagy *et al.*, 2003 85 | 24 | Liver | Tac / CsA |  | 2762 | N.A. | 36.4 | 29.2% |  |
| Jain *et al.*, 2003 4 | 49 | Liver | Tac | 98.0% | 2797 | 22% | 36.4 | 46.9% | 8.5% |
| Armenti *et al.,* 2005 79 | 70 | Kidney | Tac | 71% | 2378 | 50% | 35 | 53% |  |
| Jabiry-Zieniewicz *et al.*, 2007 86 | 21 | Liver | 71% Tac |  | 2725 | 27% | 37.0 | 38% |  |
| Kubo *et al.*, 2014 87 | 38 | Liver | 71.1% Tac | 81.6% | N.A. | 38.7% | N.A. | 32.2% |  |
| Westbrook *et al.*, 2015 78 | 81 | Liver | Tac | 68% |  | 25% |  | 29% |  |
| Kanzaki *et al.*, 2016 75 | 26 | Liver | 81% Tac | 50% | 2858 | 31% | 38 | 23% | 23% |
| Dagher *et al.*, 2018 88 | 18 | Heart | 78% Tac | 72.2% | 2418 | 46.2% | 35.1 | 53.8% |  |
| Jain *et al*., 20045 | 22 | Kidney, kidney-pancreas | Tac | 95.5% | 2373 | 28,6% (<2000 gr) | 34.4 | 45.5% | 28.6% (<25th percentile) |
| Yuksel *et al*, 2019 89 | 26 | Kidney | Tac | 100% | 2215 | 57.7% | 33.6 | 73.1% |  |
| Aktürk *et al*. 2015 48 | 16 | Kidney | Tac | 68.7% | 2540 | 45.5% |  | 36.4% |  |
| Akarsu *et al*. 2016 77 | 21 | Liver | Tac | 100% | 2993 | 18.9% | 37.09 | 23.8% |  |
|  |  |  |  |  |  |  |  |  |  |
| Jain *et al*., 1997 47 | 27 | Liver | Tac | N.A. | 2638 |  | 36.6 | 52% | 20% (<10th percentile) |
| Mohamed-Ahmed *et al*. 2014 90 | 76 | Liver  Heart, lung | 76% Tac | 91% | 2698  2364 | 37%  54% | 35.5 | 42%  54% | 16-21%  8-23% |
| Kennedy *et al*, 2012 36 | 29 | Kidney | Tac | 79.3% | 3000 | 56.5% | 36.2 | 34% |  |
| Garcia-Donaire *et al.,* 2005 91 | 19 | Kidney | Tac |  |  |  |  |  | 10% |
| Al-Otaibi *et al*, 2019 92 | 33 | Kidney | Tac | 90.6 |  |  |  | 6.1% |  |
| Coscia *et al*., 2014 80 | 385  200  56  52 | Kidney  Liver  Pancreas- kidney  Heart | Tac  Tac  Tac  Tac | 71%  72.7%  66%  67% | 2489  2757  2183  2570 | 43%  30%  58%  36% | 35.4  36.1  34  36.2 | 53%  43%  73%  47% |  |
| Christopher *et al*. 2006 73 | 43 | Liver | Tac | 67.4% | 2660 | 31% | 37.5 |  |  |
| Dinelli *et al*., 2017 93 | 26 | Kidney | 72% Tac |  | 2630 |  | 36.9 | 51.9% | 40.7% |
| D’Souza *et al*., 2018 74 | 17 | Heart | 88% Tac | 81% | 2495 |  | 35 | 46.2% | 15.4% |
| Armenti *et al*., 2000 83 | 18 | Liver | Tac | 78.2% | 2617 | 43% | 37.4 | 43% |  |
| Jabiry-Zieniewicz *et al*., 2005 94 | 11 | Liver | 72.3% Tac | 100% | 2629 |  | 36.5 | 45.5% |  |
| Kamarajah *et al*., 2018 95 | 74 | Liver | Tac | 65% |  |  |  | 57% |  |
| Madej *et al.*, 2016 96 | 101 | Liver  Kidney | 76.8% Tac  46.6% Tac |  | 3244  2429 |  | 36.6  35.4 | 42.8%  71.1% |  |
| Miller *et al.*, 2000 97 | 8 | Liver | 50% Tac | 85.7% | 2010 | 50% | 29.1 |  |  |
| Perales-Puchalt *et al.*, 2012 98 | 9 | Kidney | Tac | 100% | 2800 | N.A. | 37.3 | 33.3% | 11.1% |
| Costa *et al.*, 2011 9 | 4 | Liver | Tac | 100% | 2721 | 50% | 36.9 | 25% | N.A. |
| Songin *et al.*, 2014 99 | 43  48 | 21 Kidney  38 Liver | Tac  Tac | -1 | 2249  2899 |  | 34.7  36.8 | 74.4%  43.8% |  |
| Ecevit *et al.*, 2012 100 | 4 | Liver | 75% Tac | 100% | 2285 | 100% | 34.5 | 75% | N.A. |
| Kim *et al*., 2015 50 | 28 | Kidney | Tac |  | 2493 | 42.9% | 35.8 | 53.6% | N.A. |
| Jabiry-Zieniewi *et al*., 2011 82 | 39 | Liver | 74.4% Tac |  | 2877 | 20% | 37.2 | 30.8% |  |
| Abbreviations: N.A., not applicable; LBW, low birth weight; Tac, tacrolimus; CsA, ciclosporin | | | | | | | | | | |

**Supplemental Digital Content 3.**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Table S3.** Case reports: pregnancy outcomes in women on MPA treatment | | | | | | |
| **Article, year** | **n** | **Medication during pregnancy** | **MPA indication** | **Newborn** | **Birth defects** | **Additional information** |
| Kylat *et al*., 2017 133 | 1 | MMF 1000 mg 2/d (0 – 4 months)  MMF 500 mg 2/d (4 months – 29 weeks)  Prednisone 10 mg/d,  Hydroxychloroquine 200 mg/d  Low-molecular-weight heparin 65 mg 2/d  Aspirin mg 81 /d | SLE | Male  29 weeks  1295 g | Tricuspid regurgitation  Right ventricular hypertrophy  Patent ductus arteriosus  Atrial septal defect  TAPVR |  |
| Lin *et al*., 2011 134 | 1 | MMF 1000 mg/day (0- 3 months)  Prednisone 5 mg/d  Tacrolimus 6 mg/d  Omeprazole 20 mg/d,  Ferrous sulphate 600 mg/d | KTx | Male  40 weeks  2064 g | Bilateral microtia  Absent external auditory meatus  Enlarged fontanelle  Bilateral microphthalmia  Micrognathia  Moderate ankylosis of the jaw  Cleft of the hard and soft palate  Double outlet right ventricle  Mitral atresia  Pulmonic stenosis  TAPVR |  |
| Parisi *et al*., 2008 135 | 1 | MMF 250 mg 2/d  Tacrolimus 5 mg/d  Prednisone 5 mg/d  Norvasc  Metoprolol  Lasix  Epogen  Acyclovir (0 – 1st month) | Lupus nephritis | Female  35 weeks  2136 g | Congenital diaphragmatic hernia  Microtia  Esophageal atresia  Tracheoesophageal fistula  Cleft palate  Congenital heart defect  Digital anomalies  Dysmorphic facial features |  |
| Ang *et al*., 2008 136 | 1 | 1st pregnancy:  MMF 500 mg 3/d (week 0- 5)  2nd pregnancy:  MMF 4000 mg (for 4 days in week 7) | Recurrent erythema multiforme | -  Female  40 weeks  2900 g | Bilateral microtia  Absent external ear canals  Unilateral inferonasal iris  Chorioretinal coloboma | Miscarriage after week 7 |
| Alsebayel *et al*., 2018 137 | 1 | 1st, 2nd, 3rd pregnancy  MMF  Prednisolone 5mg/d  Tacrolimus  Lamivudine  4th pregnancy  MMF (week 0 - 20) | Ltx | Male  38 weeks  - | -  Tracheoesophageal fistula  Esophageal atresia  Bilateral ear canal atresia (microtia) | 3 miscarriages  Week 6  Week 6  Week 9 |
| Perez-Aytes *et al*., 2008 138 | 1 | MMF 500 mg/day (stopped at 10 weeks)  Tac 12 mg/day | Ktx | Female  41 weeks  3050 g | Cleft lip and palate  Bilateral microtia  Atretic external auditory canals  Chorioretinal coloboma  Hypertelorism  Micrognathia |  |
| Perales-Puchalt *et al*., 2012 98 | 1 | MMF | Ktx | - | Cleft palate  Bilateral microtia  External auditory conduct atresia  Micrognathia  Hypertelorism  Coloboma |  |
| Anderka *et al*, 2009 139 | 1 | MMF 1000 mg 2/d (discontinued at 12 weeks)  Prednisone  Lisinopril (discontinued  Hydroxychloroquine (discontinued)  Oral iron  Prenatal vitamins  Calcium  Vitamin D  Acetaminophen | SLE | Male  31 weeks  980 g | Bilateral microtia  External auditory conduct atresia  Tethered foreskin  Left hydrocele  Bilateral inguinal hernia  Sacral dimple |  |
| Jackson *et al*., 2009 140 | 1 | MMF 1000 mg 2/d (week 0-17)  MMF 500 mg 2/d (week 17-35)  Tac 5 mg 2/d  Prednisone 2.5 mg 2/d  Prenatal vitamins  Folic acid  Bactrim 800 mf 2/d (week 17-27)  Acyclovir 400 mf 2/d (week 17-27) | Ltx | Female  35 weeks  - | Bilateral cleft lip and palate  Double-outlet right ventricle  Mitral stenosis  Anterior and rightward aorta  Mild valvular pulmonary stenosis  Moderate hypoplasia left ventricle  Cataracts  Left microphthalmia  Ocular hypertelorism  Microtia  External ear canal atresia  Intestinal malrotation  Overlapping fingers  Segmental anomalies of the T2–T5 vertebral bodies, fusion of the 4th and 5th ribs on the right and 3rd, 4th, and 5th ribs on the left. |  |
| Sifontis *et al*., 2006 130 | 4 | MMF 1000 mg 2/d (week 0-26)  MMF 500 mg 2/d (week 26 -34)  Tac  Prednisone  MMF 500 mg 2/d (week 0-24)  Sirolimus (week 24-31)  Tac  Prednisone  Corticosteroids + thymoglobulin (week 24)  MMF 250 mg 2/d  Tac  Prednisone  MMF 1000 mg 2/d (0 - 2nd trimester)  Tac  Prednisone | Ktx  Ktx  Ktx  Ktx | -  34 weeks  2440 g  -  31 weeks  1531 g  -  35 weeks  2155 g  -  39 weeks  2886 g | Hypoplastic nails  Shortened fifth fingers  Cleft lip and palate  Microtia  Cleft lip and palate  Microtia  Congenital diaphragmatic hernia  Congenital heart defects  Microtia | Died 1 day after delivery |
| Schoner *et al*., 2008 141 | 1 | MMF 750 mg 2/d (week 0-8)  AZA (week 8 – 17)  Cyclophosphamide | SLE | Female  Termination at 17 weeks | Facial clefts  Bilateral transverse mouth cleft  Macrostomia  Bilateral oblique clefts  Short nose  Hypoplastic  Rudimentary premaxilla  Colobomas  Microretrognathia  rudimentary auricles  Atretic auditory canals  Hypoplastic thymus and lungs  Subaortic ventricular septal defect  Overriding common truncus arteriosus  Esophageal atresia  Tracheo-esophageal fistula  Aberrant right subclavian  Single umbilical artery  Left renal agenesis  Ipsilateral streak gonad  Mild hydrocephaly  Agenesis of the corpus callosum |  |
| Pérgola *et al*., 2001 142 | 1 | MMF 1000 mg 2/d (day 0- 100)  MMF 500 mg 2/d (day > 100)  Prednisone 25 mg/d  Tacrolimus 7 mg 2/d  Cefepime  Vancomycin  Nifedipine 30 mg/d  Trimethoprim  Nystatin  Multivitamin tablets  Acyclovir 800 mg 3/d  Famotidine 20 mg 2/d | Ktx | Female  2250 g | Hypoplastic nails  Shortened fifth fingers | 2 healthy children using prednisone, cyclosporine, and azathioprine |
| Martín *et al*., 2014 143 | 4 | MMF 1000 mg  Tacrolimus  Meprednisone  Erythropoietin  Diltiazem  Enalapril  Amlodipine  MMF (until week 8)  Methylprednisone  Enoxaparin  MMF (until week 8)  Azathioprine  Hydroxychloroquine  Prednisolone  Calcium  MMF (until week 6)  Cyclosporine  Meprednisone  Azathioprine (week 14- delivery)  Usodeoxycholic acid (week 28 – delivery)  Cholestyramine (week 28 – delivery)  Diphenhydramine | Ktx  SLE  SLE  Ktx | Female  35 weeks  1550 g  Female  36 weeks  2180 g  Female  37 weeks  2370 g  male  35 weeks  1610 g | Dysplastic ears with absent antihelix  Type I esophageal atresia  Patent foramen ovale  Microphthalmia  Right upper eyelid coloboma  Bilateral microtia  Retrognathia  Complete bilateral cleft lip and palate  Dorsal hemivertebrae  Type III esophageal atresia  Atrioventricular canal  Patent ductus arteriosus  Complete unilateral cleft lip and palate  Bilateral microtia  Absent left external ear canal  Ocular hypertelorism  Bilateral coloboma of iris  Choroid and retina  Esophageal atresia  Lumbar vertebral anomalies  Patent ductus arteriosus  Type III esophageal atresia  Dorsal hemivertebrae | Child died 3 days after delivery  Child died 4 days after delivery  Child died 2 days after delivery |
| Le Ray *et al*., 2004 144 | 1 | MMF 500 mg/d  (switch to Azathioprine 50 mg/d after week 13)  Tacrolimus 9 mg/d  Prednisone 15 mg/d | Ktx | -  22 weeks  - | Left cleft lip and palate  Micrognathia  Ocular hypertelorism  Microtia  External auditory duct atresia  Left pelvic ectopic kidney  Midline anomalies including complete agenesis of the corpus callosum | Terminated after 22 weeks |
| Koshy *et al*., 2010 145 | 1 | MMF 250 mg 2/d  Tacrolimus 2 mg 2/d  Cyclosporine A 175 mg 2/d  Prednisolone 5 mg  Labetolol 200 mg 2/d | Ktx | Male  32 weeks | Microtia  Bilateral atresia of auditory canals  Mild facial dysmorphism  Downslanted palpebral fissures  Narrow jaw with mild retrognathia  Bifid uvula |  |
| Hoeltzenbein *et al*., 2012 131 | 7 | MMF 750 mg/day (week 0-8)  Prednisone  Azathioprine  Enalapril  Hydroxychloroquine  Alendronate  acetylsalicylic acid  MMF 500 mg/day (week 0-41)  Prednisone  Tacrolimus  Acebutolol  MMF 500 mg/day (week 0-10)  Escitalopram  Lorazepam  Zolpidem  MMF (week 0-8 + 26-36)  Prednisone  Tacrolimus  Azathioprine  Fosfomycin (wk 14)  MMF 1000 mg (week 0-18)  Prednisone  Cyclosporine  Ursodeoxycholic acid  MMF 1440 mg/day (week 0-5)  Abatacept  Naproxen  Prednisolone  colchicine  valaciclovir  MMF (week 0-8)  Prednisone, azathioprine, methyldopa | SLE  Ktx  SLE  Ktx  Ltx  Hyper IgD syndrome | Male  -  -  -  41 weeks  -  Female  35 weeks  -  31 weeks  -  36 weeks  -  -  36 weeks  - | Microtia  EACA  Colobomal cyst  Olfactory nerve agenesis  Hypertelorism  Malar hypoplasia  Brachycephaly  Microretrognathia  esophageal atresia type III  retroesophageal right subclavian artery  Campto‐/clinodactylia  Microtia  External Auditory Canal Atresia  benign cyst right kidney  Tracheo‐esophageal atresia type 3  Hydronephrosis  Autism  ASD II  Asymmetry of brain ventricles  Occipital meningocele  dysplastic left cerebellar hemisphere  EACA | Pregnancy terminated at 26 weeks |
| Dei Malatesta *et al*., 2009 146 | 1 | MMF 500mg/day  Tac 4 mg/day  Prednisone 5 mg every other day | KTx | Male  37 weeks  2850 g | Unilateral coloboma |  |
| Andrade Vila *et al*., 2008 147 | 1 | MMF 500 mg/BID  (after 5 weeks 250mg/BID)  Tacrolimus 3 mg/BID  Prednisone 5mg/day  Pravastatin 40mg/day  Diltiazem 60 mg/TID  carbamazepine | Htx | -  -  - | Left eye microphthalmia  Complete atresia of the auditory conduit and middle ear bilaterally  Palatine gap  Bad formation of auricular pavilion  Umbilical hernia  Pulmonary valve stenosis 15 mmHg |  |
| Huang *et al*., 2008 151 | 1 | MMF 1000mg 2dd (week 0-12)  Prednisolone  Hydroxychloroquine | SLE | Female  22 weeks  - | Micrognathia  Ocular hypertelorism  Bilateral microtia  External auditory duct atresia  Nasal bifid anomaly | Pregnancy terminated at 22 weeks |
| Tjeertes *et al*., 2007 148 | 1 | MMF (week 0-20)  Prednisolone  Darbepoetin alfa  Methyldopa | KTx | male  35 weeks  2330 g | Ear malformation  Non-immune hydrops fetalis | Fetal anemia |
| Velinov and Zellers *et al*., 2008 152 | 1 | MMF 500 mg 2dd (week 0-8)  Adalimumab 40 mg | Lupus nephritis | Female  32 weeks  4422 g | Hypertelorism  Epicanthal folds  Arching eyebrows  Thick everted lower lip  Bilateral microtia with aural atresia  Cleft palate  Congenital tracheomalacia  Brachydactyly  Developmental delay |  |
| El Sebaaly *et al*., 2007 153 | 1 | MMF 1000 mg bid (week 0-25)  Prednisone  Hydroxychloroquine  perindopril | Lupus nephritis |  | Bilateral anotia  External auditory duct atresia  Polydactyly  Nail hypoplasia  Kidney asymmetry  Anterior positioning of the aorta  Interventricular communication | Pregnancy was terminated |
| Ruiz-Campillo *et al*., 2008 154 | 1 | MMF 1500 mg/day (whole pregnancy)  Deflazacort 90 mg/day | SLE with severe lupus nephritis | Female  31 weeks  1035 g | Cleft palate  Microretrognathia |  |
| Källén *et al*., 2005 149 | 1 | MMF (early pregnancy)  Tac  Prednisolone  Ursodeoxycholic acid | LTx | -  -  - | Esophageal atresia  Complex cardiac defect  Iris anomaly |  |
| Zahra *et al*., 2009 150 | 2 | MMF 1000mg (week 0-12)  Cyclosporine 200mg (week 0-12)  Cyclosporine 300mg (week 12-38)  MMF  Cyclosporine 200mg  Prednisolone 5 mg | LTx  LTx | Female  38 weeks  2480 g  Male  38 weeks  3100 g | -  - |  |
| Abbreviations: MMF, mycophenolate mofetil; Tac, tacrolimus; SLE, systemic lupus erythematosus; KTx, kidney transplantation; LTx, liver transplantation; HTx, heart transplantation; TAPVR, total anomalous pulmonary venous return  Table adapted from Perez-Aytes138, Merlob156, and Anderka139. | | | | | | |